Savient Pharmaceuticals Inc  

(Public, OTCMKTS:SVNTQ)   Watch this stock  
Find more results for NASDAQ:SVNT
0.0019
May 30 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.91
Open     -
Vol / Avg. 0.00/340,036.00
Mkt cap 139,409.00
P/E     -
Div/yield     -
EPS -1.37
Shares 73.37M
Beta 1.80
Inst. own 4%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -311.16% -656.45%
Operating margin -202.82% -539.85%
EBITD margin - -658.33%
Return on average assets -126.19% -74.80%
Return on average equity - -
Employees 122 -
CDP Score - -

Address

ONE TOWER CENTER
EAST BRUNSWICK, NJ 8816
United States - Map
+1-732-4189300 (Phone)
+1-302-6555049 (Fax)

Website links

Description

Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.